ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells

BACKGROUND: Most melanoma patients with BRAF(V600E) positive tumors respond well to a combination of BRAF kinase and MEK inhibitors. However, some patients are intrinsically resistant while the majority of patients eventually develop drug resistance to the treatment. For patients insufficiently resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Cesi, Giulia, Walbrecq, Geoffroy, Zimmer, Andreas, Kreis, Stephanie, Haan, Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465587/
https://www.ncbi.nlm.nih.gov/pubmed/28595656
http://dx.doi.org/10.1186/s12943-017-0667-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465587/
https://www.ncbi.nlm.nih.gov/pubmed/28595656
http://dx.doi.org/10.1186/s12943-017-0667-y

Ejemplares similares